Accelerated waning of the humoral response to COVID-19 vaccines in obesity.

Humans COVID-19 Vaccines Obesity, Morbid Longitudinal Studies Prospective Studies COVID-19 / epidemiology SARS-CoV-2 Obesity / epidemiology Antibodies, Neutralizing Antibodies, Viral Vaccination

Journal

Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015

Informations de publication

Date de publication:
05 2023
Historique:
received: 09 08 2022
accepted: 07 04 2023
medline: 24 5 2023
pubmed: 12 5 2023
entrez: 11 5 2023
Statut: ppublish

Résumé

Obesity is associated with an increased risk of severe Coronavirus Disease 2019 (COVID-19) infection and mortality. COVID-19 vaccines reduce the risk of serious COVID-19 outcomes; however, their effectiveness in people with obesity is incompletely understood. We studied the relationship among body mass index (BMI), hospitalization and mortality due to COVID-19 among 3.6 million people in Scotland using the Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) surveillance platform. We found that vaccinated individuals with severe obesity (BMI > 40 kg/m

Identifiants

DOI: 10.1038/s41591-023-02343-2 PMID: 37169862 PMC: PMC10202802
pubmed: 37169862
doi: 10.1038/s41591-023-02343-2
pii: 10.1038/s41591-023-02343-2
pmc: PMC10202802
doi:

Substances chimiques

COVID-19 Vaccines 0
Antibodies, Neutralizing 0
Antibodies, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1146-1154

Subventions

Organisme : Medical Research Council
ID : MC_PC_19075
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/B/000C0433
Pays : United Kingdom
Organisme : MRF
ID : MRF_MRF-057-0002-RG-THAV-C0798
Pays : United Kingdom
Organisme : NIAID NIH HHS
ID : U19 AI082630
Pays : United States
Organisme : Medical Research Council
ID : MR/W020564/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_0025/12
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 208363/Z/17/Z
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/T032413/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : WT109965MA
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_20058
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_PC_19004
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/B/000C0427
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/B/000C0428
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 204845/Z/16/Z
Pays : United Kingdom

Informations de copyright

© 2023. The Author(s).

Références

Popkin, B. M. et al. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes. Rev. 21, e13128 (2020).
pubmed: 32845580 pmcid: 7461480 doi: 10.1111/obr.13128
Gao, M. et al. Associations between body-mass index and COVID-19 severity in 6.9 million people in England: a prospective, community-based, cohort study. Lancet Diabetes Endocrinol. 9, 350–359 (2021).
pubmed: 33932335 pmcid: 8081400 doi: 10.1016/S2213-8587(21)00089-9
Arbel, R. et al. BNT162b2 vaccine booster and mortality due to Covid-19. N. Engl. J. Med. 385, 2413–2420 (2021).
pubmed: 34879190 doi: 10.1056/NEJMoa2115624
Barron, E. et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 8, 813–822 (2020).
pubmed: 32798472 pmcid: 7426088 doi: 10.1016/S2213-8587(20)30272-2
Grasselli, G. et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 323, 1574–1581 (2020).
pubmed: 32250385 pmcid: 7136855 doi: 10.1001/jama.2020.5394
Dashtban, A. et al. A retrospective cohort study predicting and validating impact of the COVID-19 pandemic in individuals with chronic kidney disease. Kidney Int. 102, 652–660 (2022).
pubmed: 35724769 pmcid: 9212366 doi: 10.1016/j.kint.2022.05.015
Alvarez-Garcia, J. et al. Prognostic impact of prior heart failure in patients hospitalized with COVID-19. J. Am. Coll. Cardiol. 76, 2334–2348 (2020).
pubmed: 33129663 pmcid: 7598769 doi: 10.1016/j.jacc.2020.09.549
Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
pubmed: 33301246 doi: 10.1056/NEJMoa2034577
Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).
pubmed: 33378609 doi: 10.1056/NEJMoa2035389
Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205–1211 (2021).
pubmed: 34002089 doi: 10.1038/s41591-021-01377-8
Edara, V. V. et al. Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. N. Engl. J. Med. 385, 664–666 (2021).
pubmed: 34233096 doi: 10.1056/NEJMc2107799
Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science 375, 43–50 (2022).
pubmed: 34812653 doi: 10.1126/science.abm3425
Katikireddi, S. V. et al. Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil. Lancet 399, 25–35 (2022).
pubmed: 34942103 pmcid: 8687670 doi: 10.1016/S0140-6736(21)02754-9
Goldberg, Y. et al. Waning immunity after the BNT162b2 vaccine in Israel. N. Engl. J. Med. 385, e85 (2021).
pubmed: 34706170 doi: 10.1056/NEJMoa2114228
Eliakim, A., Schwindt, C., Zaldivar, F., Casali, P. & Cooper, D. M. Reduced tetanus antibody titers in overweight children. Autoimmunity 39, 137–141 (2006).
pubmed: 16698670 pmcid: 4623573 doi: 10.1080/08916930600597326
Painter, S. D., Ovsyannikova, I. G. & Poland, G. A. The weight of obesity on the human immune response to vaccination. Vaccine 33, 4422–4429 (2015).
pubmed: 26163925 pmcid: 4547886 doi: 10.1016/j.vaccine.2015.06.101
Sheridan, P. A. et al. Obesity is associated with impaired immune response to influenza vaccination in humans. Int. J. Obes. (Lond.) 36, 1072–1077 (2012).
pubmed: 22024641 doi: 10.1038/ijo.2011.208
Banga, N., Guss, P., Banga, A. & Rosenman, K. D. Incidence and variables associated with inadequate antibody titers after pre-exposure rabies vaccination among veterinary medical students. Vaccine 32, 979–983 (2014).
pubmed: 24394442 doi: 10.1016/j.vaccine.2013.12.019
Levin, E. G. et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N. Engl. J. Med. 385, e84 (2021).
pubmed: 34614326 doi: 10.1056/NEJMoa2114583
Herzberg, J. et al. Persistence of immune response in health care workers after two doses BNT162b2 in a longitudinal observational study. Front. Immunol. 13, 839922 (2022).
pubmed: 35309303 pmcid: 8931311 doi: 10.3389/fimmu.2022.839922
Yamamoto, S. et al. Sex-associated differences between BMI and SARS-CoV-2 antibody titers following the BNT162b2 vaccine. Obes. (Silver Spring) 30, 999–1003 (2022).
doi: 10.1002/oby.23417
Papadopoulos, D. et al. Predictive factors for neutralizing antibody levels nine months after full vaccination with BNT162b2: results of a machine learning analysis. Biomedicines 10, 204 (2022).
Ward, H. et al. Population antibody responses following COVID-19 vaccination in 212,102 individuals. Nat. Commun. 13, 907 (2022).
pubmed: 35173150 pmcid: 8850615 doi: 10.1038/s41467-022-28527-x
Mallow, C. et al. Real world SARS-COV-2 vaccine effectiveness in a Miami academic institution. Am. J. Emerg. Med. 54, 97–101 (2022).
pubmed: 35151018 pmcid: 8810434 doi: 10.1016/j.ajem.2022.01.066
Chhabria, S. & Stanford, F. C. A long shot: the importance of needle length in vaccinating patients with obesity against COVID-19. Vaccine 40, 9–10 (2022).
pubmed: 34794822 doi: 10.1016/j.vaccine.2021.11.008
Mulholland, R. H. et al. Cohort profile: Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II) database. Int. J. Epidemiol. 50, 1064–1074 (2021).
pubmed: 34089614 doi: 10.1093/ije/dyab028
Agrawal, U. et al. COVID-19 hospital admissions and deaths after BNT162b2 and ChAdOx1 nCoV-19 vaccinations in 2.57 million people in Scotland (EAVE II): a prospective cohort study. Lancet Respir. Med. 9, 1439–1449 (2021).
pubmed: 34599903 pmcid: 8480963 doi: 10.1016/S2213-2600(21)00380-5
Simpson, C. R. et al. Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II): protocol for an observational study using linked Scottish national data. BMJ Open 10, e039097 (2020).
pubmed: 32565483 pmcid: 7311023 doi: 10.1136/bmjopen-2020-039097
Vasileiou, E. et al. Investigating the uptake, effectiveness and safety of COVID-19 vaccines: protocol for an observational study using linked UK national data. BMJ Open 12, e050062 (2022).
pubmed: 35165107 doi: 10.1136/bmjopen-2021-050062
Gerber, P. P. et al. A protease-activatable luminescent biosensor and reporter cell line for authentic SARS-CoV-2 infection. PLoS Pathog. 18, e1010265 (2022).
pubmed: 35143592 pmcid: 8865646 doi: 10.1371/journal.ppat.1010265
Burton, A. R. et al. The memory B cell response to influenza vaccination is impaired in older persons. Cell Rep. 41, 111613 (2022).
pubmed: 36351385 pmcid: 9666924 doi: 10.1016/j.celrep.2022.111613
Cancro, M. P. Age-associated B cells. Annu. Rev. Immunol. 38, 315–340 (2020).
pubmed: 31986068 doi: 10.1146/annurev-immunol-092419-031130
Hill, D. L. et al. The adjuvant GLA-SE promotes human Tfh cell expansion and emergence of public TCRβ clonotypes. J. Exp. Med. 216, 1857–1873 (2019).
pubmed: 31175140 pmcid: 6683991 doi: 10.1084/jem.20190301
Garcia-Beltran, W. F. et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell 184, 476–488 (2021).
pubmed: 33412089 doi: 10.1016/j.cell.2020.12.015
Rees-Spear, C. et al. The effect of spike mutations on SARS-CoV-2 neutralization. Cell Rep. 34, 108890 (2021).
pubmed: 33713594 pmcid: 7936541 doi: 10.1016/j.celrep.2021.108890
Bergwerk, M. et al. Covid-19 breakthrough infections in vaccinated health care workers. N. Engl. J. Med. 385, 1474–1484 (2021).
pubmed: 34320281 doi: 10.1056/NEJMoa2109072
Neidich, S. D. et al. Increased risk of influenza among vaccinated adults who are obese. Int. J. Obes. (Lond.) 41, 1324–1330 (2017).
pubmed: 28584297 doi: 10.1038/ijo.2017.131
Ward, Z. J. et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N. Engl. J. Med. 381, 2440–2450 (2019).
pubmed: 31851800 doi: 10.1056/NEJMsa1909301
Simpson, C. R. et al. External validation of the QCovid risk prediction algorithm for risk of COVID-19 hospitalisation and mortality in adults: national validation cohort study in Scotland. Thorax 77, 497–504 (2022).
pubmed: 34782484 doi: 10.1136/thoraxjnl-2021-217580
Public Health Scotland. Public Health Scotland COVID-19 & Winter Statistical Report. https://publichealthscotland.scot/media/10853/21-12-15-covid19-winter_publication_report.pdf (2021).
Xiong, X. et al. A thermostable, closed SARS-CoV-2 spike protein trimer. Nat. Struct. Mol. Biol. 27, 934–941 (2020).
pubmed: 32737467 pmcid: 7116388 doi: 10.1038/s41594-020-0478-5
Daly, J. L. et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Science 370, 861–865 (2020).
pubmed: 33082294 pmcid: 7612957 doi: 10.1126/science.abd3072
Patterson, E. I. et al. Methods of inactivation of SARS-CoV-2 for downstream biological assays. J. Infect. Dis. 222, 1462–1467 (2020).
pubmed: 32798217 doi: 10.1093/infdis/jiaa507
Meng, B. et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature 603, 706–714 (2022).
pubmed: 35104837 pmcid: 8942856 doi: 10.1038/s41586-022-04474-x
Bergamaschi, L. et al. Longitudinal analysis reveals that delayed bystander CD8
pubmed: 34051148 pmcid: 8125900 doi: 10.1016/j.immuni.2021.05.010
Andreasson, U. et al. A practical guide to immunoassay method validation. Front. Neurol. 6, 179 (2015).
pubmed: 26347708 pmcid: 4541289 doi: 10.3389/fneur.2015.00179
Harvala, H. et al. Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization. Transfusion 62, 1347–1354 (2022).
pubmed: 35588314 pmcid: 9348319 doi: 10.1111/trf.16934
Knezevic, I. et al. WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: call for urgent action by the scientific community. Lancet Microbe 3, e235–e240 (2022).
pubmed: 34723229 pmcid: 8547804 doi: 10.1016/S2666-5247(21)00266-4
Angyal, A. et al. T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. Lancet Microbe 3, e21–e31 (2022).
pubmed: 34778853 pmcid: 8577846 doi: 10.1016/S2666-5247(21)00275-5
Silva-Cayetano, A. et al. A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice. Med. (N Y) 2, 243–262 (2021).
Foster, W. S. et al. Tfh cells and the germinal center are required for memory B cell formation & humoral immunity after ChAdOx1 nCoV-19 vaccination. Cell Rep. Med. 3, 100845 (2022).
pubmed: 36455555 pmcid: 9663747 doi: 10.1016/j.xcrm.2022.100845
Pasciuto, E. et al. Microglia require CD4 T cells to complete the fetal-to-adult transition. Cell 182, 625–640 (2020).
pubmed: 32702313 pmcid: 7427333 doi: 10.1016/j.cell.2020.06.026

Auteurs

Agatha A van der Klaauw (AA)

University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome-Medical Research Council (MRC) Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
ORCID: 0000-0001-6971-8828

Emily C Horner (EC)

MRC Toxicology Unit, University of Cambridge, Cambridge, UK.
ORCID: 0000-0003-2226-1028

Pehuén Pereyra-Gerber (P)

Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, UK.
Department of Medicine, University of Cambridge, Cambridge, UK.

Utkarsh Agrawal (U)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
ORCID: 0000-0001-5181-6120

William S Foster (WS)

Babraham Institute, Babraham Research Campus, Cambridge, UK.
ORCID: 0000-0002-7103-3657

Sarah Spencer (S)

MRC Toxicology Unit, University of Cambridge, Cambridge, UK.

Bensi Vergese (B)

University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome-Medical Research Council (MRC) Institute of Metabolic Science, University of Cambridge, Cambridge, UK.
NIHR Cambridge Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Miriam Smith (M)

University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome-Medical Research Council (MRC) Institute of Metabolic Science, University of Cambridge, Cambridge, UK.

Elana Henning (E)

University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome-Medical Research Council (MRC) Institute of Metabolic Science, University of Cambridge, Cambridge, UK.

Isobel D Ramsay (ID)

Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, UK.
Department of Medicine, University of Cambridge, Cambridge, UK.
Department of Infectious Diseases, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
ORCID: 0000-0002-9954-2023

Jack A Smith (JA)

Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, UK.
Department of Medicine, University of Cambridge, Cambridge, UK.
ORCID: 0000-0001-6654-5706

Stephane M Guillaume (SM)

Babraham Institute, Babraham Research Campus, Cambridge, UK.
ORCID: 0000-0003-2007-4608

Hayley J Sharpe (HJ)

Babraham Institute, Babraham Research Campus, Cambridge, UK.
ORCID: 0000-0002-4723-298X

Iain M Hay (IM)

Babraham Institute, Babraham Research Campus, Cambridge, UK.
Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK.
ORCID: 0000-0002-5451-1768

Sam Thompson (S)

Babraham Institute, Babraham Research Campus, Cambridge, UK.

Silvia Innocentin (S)

Babraham Institute, Babraham Research Campus, Cambridge, UK.

Lucy H Booth (LH)

MRC Toxicology Unit, University of Cambridge, Cambridge, UK.

Chris Robertson (C)

Department of Mathematics and Statistics, University of Strathclyde, Glasgow, UK.

Colin McCowan (C)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
ORCID: 0000-0002-9466-833X

Steven Kerr (S)

Usher Institute, University of Edinburgh, Edinburgh, UK.

Thomas E Mulroney (TE)

MRC Toxicology Unit, University of Cambridge, Cambridge, UK.

Martin J O'Reilly (MJ)

MRC Toxicology Unit, University of Cambridge, Cambridge, UK.
ORCID: 0000-0003-1095-0328

Thevinya P Gurugama (TP)

MRC Toxicology Unit, University of Cambridge, Cambridge, UK.

Lihinya P Gurugama (LP)

MRC Toxicology Unit, University of Cambridge, Cambridge, UK.

Maria A Rust (MA)

MRC Toxicology Unit, University of Cambridge, Cambridge, UK.

Alex Ferreira (A)

MRC Toxicology Unit, University of Cambridge, Cambridge, UK.
ORCID: 0000-0002-1964-1049

Soraya Ebrahimi (S)

Immunology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Clinical Biochemistry, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Lourdes Ceron-Gutierrez (L)

Immunology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Clinical Biochemistry, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Jacopo Scotucci (J)

University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome-Medical Research Council (MRC) Institute of Metabolic Science, University of Cambridge, Cambridge, UK.

Barbara Kronsteiner (B)

Peter Medawar Building for Pathogen Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
ORCID: 0000-0003-0867-2867

Susanna J Dunachie (SJ)

Peter Medawar Building for Pathogen Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
NDM Centre for Global Health Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Translational Gastroenterology Unit, University of Oxford, Oxford, UK.
Mahidol-Oxford Tropical Medicine Research Unit, Bangkok, Thailand.
ORCID: 0000-0001-5665-6293

Paul Klenerman (P)

Peter Medawar Building for Pathogen Research, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
NDM Centre for Global Health Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Translational Gastroenterology Unit, University of Oxford, Oxford, UK.
ORCID: 0000-0003-4307-9161

Adrian J Park (AJ)

Clinical Biochemistry, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
ORCID: 0000-0003-2713-7595

Francesco Rubino (F)

Department of Diabetes, King's College London and King's College Hospital NHS Foundation Trust, London, UK.

Abigail A Lamikanra (AA)

NHS Blood and Transplant, Oxford, UK.
Radcliffe Department of Medicine, University of Oxford, Oxford, UK.

Hannah Stark (H)

NIHR BioResource, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Nathalie Kingston (N)

NIHR BioResource, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Lise Estcourt (L)

NHS Blood and Transplant, Oxford, UK.
Radcliffe Department of Medicine, University of Oxford, Oxford, UK.

Heli Harvala (H)

NHS Blood and Transplant, London, UK.

David J Roberts (DJ)

NHS Blood and Transplant, Oxford, UK.
Radcliffe Department of Medicine, University of Oxford, Oxford, UK.

Rainer Doffinger (R)

Immunology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
Clinical Biochemistry, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.

Michelle A Linterman (MA)

Babraham Institute, Babraham Research Campus, Cambridge, UK.
ORCID: 0000-0001-6047-1996

Nicholas J Matheson (NJ)

Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, UK.
Department of Medicine, University of Cambridge, Cambridge, UK.
Department of Infectious Diseases, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
NHS Blood and Transplant, Cambridge, UK.
ORCID: 0000-0002-3318-1851

Aziz Sheikh (A)

Usher Institute, University of Edinburgh, Edinburgh, UK. aziz.sheikh@ed.ac.uk.
ORCID: 0000-0001-7022-3056

I Sadaf Farooqi (IS)

University of Cambridge Metabolic Research Laboratories and NIHR Cambridge Biomedical Research Centre, Wellcome-Medical Research Council (MRC) Institute of Metabolic Science, University of Cambridge, Cambridge, UK. isf20@cam.ac.uk.
ORCID: 0000-0001-7609-3504

James E D Thaventhiran (JED)

MRC Toxicology Unit, University of Cambridge, Cambridge, UK. jedt2@cam.ac.uk.
ORCID: 0000-0001-8616-074X

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Accelerated waning of the humoral response to...
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Vaccins › Vaccins antiviraux › Vaccins contre la COVID-19 › Accelerated waning of the humoral response to...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Obésité › Obésité morbide › Accelerated waning of the humoral response to...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études longitudinales › Accelerated waning of the humoral response to...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Accelerated waning of the humoral response to...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Infections de l'appareil respiratoire › Pneumopathie infectieuse › Pneumopathie virale › COVID-19 › Accelerated waning of the humoral response to...
questionsmedicales.fr › Virus › Virus à ARN › Virus à ARN à brin positif › Nidovirales › Coronaviridae › Coronavirus › Betacoronavirus › Virus du SRAS › SARS-CoV-2 › Accelerated waning of the humoral response to...
questionsmedicales.fr › États, signes et symptômes pathologiques › Signes et symptômes › Obésité › Accelerated waning of the humoral response to...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps neutralisants › Accelerated waning of the humoral response to...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps antiviraux › Accelerated waning of the humoral response to...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pratiques en santé publique › Prévention primaire › Immunisation › Vaccination › Accelerated waning of the humoral response to...